One-carbon Therapeutics has closed an oversubscribed 153 million SEK ($16.2 million) private placement financing round supported by current and new investors and private Swedish family offices. The company says it will use the net proceeds from the private placement to strengthen its financial position and expand its ongoing Phase I/II ODIN clinical study of TH9619, […]
To read this content in full, you need to login.
Not yet a DDW member? Join now for FREE – it takes less than 2 minutes!